September 29, 2020
Toronto, Ontario–(Newsfile Corp. – September 29, 2020) – Nutritional High International Inc. (CSE: EAT)
(“Nutritional High” or the “Company”) is pleased to provide an update on recent advances made by
its new Psychedelic Science Corp. (PSC) business unit acquired last month (see: press release dated
August 17, 2020). PSC is focused on developing psychedelic cacti-based wellness and pharmaceutical
products to address various conditions.
PSC has been developing safety trials of certain psychedelic cacti strains with a view to assessing
safety and efficacy with respect to weight loss, insomnia, anxiety and pain. PSC has applied to the Thai
FDA which will meet US and international FDA standards.
PSC has formed a Science Committee comprised of NHII board member Dr. Jason Dyck (University of
Alberta), Dr. Duke Fu (CEO of Green Therapeutics, Nevada) and Dr. Ekapol Limpongsa (Rangsit
University, Thailand). The committee is working closely with John Durfy, CEO of Nutritional High to
prepare for the trials including:
assessing the alkaloid content of various cacti in order to select appropriate strains for trials. Over
the next 2 weeks PSC will finalize the selection of a cactus strain based on alkaloid make-up,
mescaline content, speed of growth, plant genomics and sourcing availability.
PSC has developed a proprietary whole plant extraction methodology which will be used in the
extraction process at Rangsit University.
establishing third-party supply and potentially launching a commercial grow.
The PSC team is also assessing various non-psychoactive, cactus-based wellness products which are
legal for sale and distribution in the U.S. and Canada.
John Durfy, CEO of Nutritional High commented, “We are very excited to be one of the first companies to
commence trials on the medicinal value of the cactus plant. With the progression of these trials over the
next few months, we will gain an understanding of the potential products we look to launch in 2021.”
Nutritional High Chair, Adam Szweras, added: “While we will continue to focus our efforts in the US
cannabis markets, we believe that PSC will provide the Company with a significant opportunity in the
future as the regulatory environment for psychedelic products continue to develop. While other
companies are focusing on other psychedelic plants, we believe our focus on cactus will blaze the trail
for possible wellness and pharma applications in the future.”